-
Product Insights
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
HA-MRSA Infections Drugs in Development Market Report Overview Hospital-acquired methicillin-resistant staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warmth to the touch, fever, and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device, and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures. The HA-MRSA infections Drugs in Development market research report provides comprehensive information on the therapeutics under development for HA-MRSA infections, complete with...
-
Product Insights
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Survival Motor Neuron Protein (Component of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development Report Overview Survival of motor neuron or survival motor neuron (SMN) is a protein encoded by the SMN1 and SMN2 genes. The Survival motor neuron protein (Component of Gems 1 or Gemin 1 or SMN1 or SMN2) drugs in development research report provides comprehensive information on the therapeutics under development for survival motor neuron protein. The report also analyzes the stage of...
-
Product Insights
Keloids Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Keloids are the growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing, and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroids, radiation, surgical removal, and silicone gel or patches. The Keloids pipeline drugs market research report provides comprehensive information on the therapeutics under development for Keloids, complete with analysis by stage of development,...
-
Product Insights
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hereditary Angioedema (HAE) Pipeline Drugs Development Market Overview Hereditary Angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids. The Hereditary Angioedema pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hereditary Angioedema, complete with analysis by...
-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple System Atrophy Drugs in Development Market Overview Multiple System Atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs the body's involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson medications. The Multiple System Atrophy pipeline drugs market research report provides comprehensive information on the therapeutics under development for MSA and analysis by stage of development,...
-
Product Insights
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha Synuclein (SNCA) Drugs in Development Report Overview Alpha-synuclein is a protein normally found in cells all over the body and is one of the key players in Parkinson’s disease. The Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) drugs in development research report provides comprehensive information on the therapeutics under development for Alpha Synuclein. The report also analyzes the stage of development, mechanism of action (MoA), route...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ATL-1102
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ATL-1102 Drug Details ATL-1102, (TV-1102, ISIS 107248) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – atesidorsen sodium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry atesidorsen sodium Drug Details Atesidorsen sodium (ATL-1103, COR-004) is under development for the treatment...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Respiratory syncytial virus (RSV) infection infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The Respiratory Syncytial Virus pipeline market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological...